Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

90Y-SIRT as Conversion Therapy for Unresectable Hepatocellular Carcinoma

14. november 2026 opdateret af: zhanglin, Beijing Tsinghua Chang Gung Hospital

Efficacy and Long-Term Outcomes of Yttrium-90 Treatment as Conversion Therapy for Unresectable Hepatocellular Carcinoma: A Multicenter Cohort Study

This multicenter observational study will evaluate long-term outcomes in patients with initially unresectable hepatocellular carcinoma who undergo curative-intent hepatectomy after conversion therapy. The conversion therapy is based on either yttrium-90 selective internal radiation therapy or transarterial chemoembolization. The study includes a retrospective cohort and a prospective observational cohort. The primary outcome is recurrence-free survival after surgery. Overall survival, postoperative pathological features, and perioperative outcomes will also be compared between the two groups.

Studieoversigt

Status

Ikke rekrutterer endnu

Detaljeret beskrivelse

This study includes both retrospective and prospective components. The retrospective cohort will include eligible patients who previously underwent curative-intent hepatectomy after 90Y-SIRT-based or TACE-based conversion therapy. The prospective observational cohort will consecutively enroll eligible patients after curative-intent hepatectomy and follow them prospectively for postoperative outcomes.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

200

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 102218
        • Beijing Tsinghua Changgung Hospital
        • Kontakt:
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Kina, 400038
        • Southwest Hospital, Army Medical University
        • Kontakt:
    • Fujian
      • Fuzhou, Fujian, Kina, 350025
        • Mengchao Hepatobiliary Hospital of Fujian Medical University
        • Kontakt:
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510630
        • The First Affiliated Hospital of Jinan University
        • Kontakt:
    • Liaoning
      • Shenyang, Liaoning, Kina, 110001
        • The First Hospital of China Medical University
        • Kontakt:
    • Shaanxi
      • Xi'an, Shaanxi, Kina, 710061
        • The First Affiliated Hospital of Xi'an Jiaotong University
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Sandsynlighedsprøve

Studiebefolkning

The study population consists of patients with initially unresectable HCC treated at participating centers who undergo curative-intent hepatectomy after 90Y-SIRT-based or TACE-based conversion therapy. All consecutive patients meeting the predefined eligibility criteria will be included. Patients identified from historical records will form the retrospective cohort, while patients enrolled after study initiation will form the prospective observational cohort.

Beskrivelse

Inclusion Criteria:

  1. Initially unresectable primary liver cancer.
  2. Underwent curative-intent hepatectomy following conversion therapy based on 90Y-SIRT or TACE.
  3. Postoperative histopathological examination confirmed HCC.

Exclusion Criteria:

  1. Received conversion therapy based on other locoregional treatments, such as hepatic arterial infusion chemotherapy (HAIC) or external beam radiotherapy (EBRT).
  2. Presence of extrahepatic metastasis prior to curative-intent hepatectomy.
  3. Postoperative histopathological diagnosis of intrahepatic cholangiocarcinoma (ICC) or combined hepatocellular-cholangiocarcinoma (cHCC-CCA).
  4. Failure to achieve R0 resection.
  5. Incomplete clinical data.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: OTHER

Kohorter og interventioner

Gruppe / kohorte
90Y-SIRT-Based Conversion Therapy Group

Patients with initially unresectable hepatocellular carcinoma who received conversion therapy based on yttrium-90 selective internal radiation therapy (90Y-SIRT) and subsequently underwent curative-intent hepatectomy after being deemed resectable.

TACE-Based Conversion Therapy Group

Patients with initially unresectable hepatocellular carcinoma who received conversion therapy based on transarterial chemoembolization (TACE) and subsequently underwent curative-intent hepatectomy after being deemed resectable.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Postoperative recurrence-free survival (RFS)
Tidsramme: From the date of curative-intent hepatectomy until the first tumor recurrence, death, or last follow-up, up to 5 years.
From the date of curative-intent hepatectomy until the first tumor recurrence, death, or last follow-up, up to 5 years.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Postoperative overall survival (OS)
Tidsramme: From the date of curative-intent hepatectomy until death or last follow-up, up to 10 years.
From the date of curative-intent hepatectomy until death or last follow-up, up to 10 years.
Pathological complete response (pCR) rate
Tidsramme: Immediately after curative-intent hepatectomy.

pCR is defined as the absence of residual viable tumor cells in the resected specimens. The pCR rate is calculated as the proportion of patients achieving pCR among all patients with evaluable postoperative histopathological assessments.

Immediately after curative-intent hepatectomy.
Major pathological response (MPR) rate
Tidsramme: Immediately after curative-intent hepatectomy.

MPR is defined as ≤10% residual viable tumor cells in the resected specimens. The MPR rate is calculated as the proportion of patients achieving MPR among all patients with evaluable postoperative histopathological assessments.

Immediately after curative-intent hepatectomy.
Microvascular invasion (MVI) positivity rate
Tidsramme: Immediately after curative-intent hepatectomy.
Immediately after curative-intent hepatectomy.
Satellite nodule positivity rate
Tidsramme: Immediately after curative-intent hepatectomy.
Immediately after curative-intent hepatectomy.
Postoperative complication rate
Tidsramme: Perioperatively, from curative-intent hepatectomy through hospital discharge.

The occurrence and type of postoperative complications will be recorded, and their severity will be graded according to the Clavien-Dindo classification. Bile leakage and post-hepatectomy liver failure (PHLF) will also be graded according to the ISGLS criteria.

Perioperatively, from curative-intent hepatectomy through hospital discharge.

Andre resultatmål

Resultatmål
Tidsramme
Percentage change in tumor markers
Tidsramme: From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
Percentage change in maximum tumor diameter
Tidsramme: From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Lin Zhang, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. december 2026

Primær færdiggørelse (Anslået)

1. december 2031

Studieafslutning (Anslået)

1. december 2036

Datoer for studieregistrering

Først indsendt

10. november 2026

Først indsendt, der opfyldte QC-kriterier

14. november 2026

Først opslået (Faktiske)

17. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

14. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified IPD underlying the published results may be made available upon reasonable request after publication, subject to approval by the principal investigator and applicable ethical and institutional requirements.

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner